NCT04448977Completed
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
A Biomarker for Cognitive Fatigue Using Functional Imaging in MS
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 24 (actual)
- First submitted
- 15 Jun 2020
- Start date
- 6 May 2021
- Primary completion date
- 15 Oct 2025
- Lead sponsor
- Kessler Foundation
- Diseases
- Multiple sclerosis
- NCT number
- NCT04448977
What you commit to
- Study type: Observational
- Participants enrolled: 24
- From 6 May 2021 to the primary completion date, 15 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of head injury, stroke, seizures, or any other significant neurological event other than MS
- History of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder.
- Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments.
Other
- Flare up of MS symptoms within the past month.
- left handed.
- Not able to have an MRI
Who the study is looking for
- Age between 18-64.
- Relapsing remitting multiple sclerosis
- Been newly prescribed a new disease modifying medication for MS (either Ocrevus or Copaxone)
- or healthy volunteer who can speak English fluently.
Age in the registry: 18 years to 64 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kessler Foundation Coordinator of this site? Confirm its status | West Orange | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.